1 min read

Celebrating The Success of Velcade | 14 Years Later

Last week, Veristat attended the Massachusetts Biotechnology Council (MassBio) forum titled “Evolution of an Academic Discovery: First Person Account of the Development of Velcade®”.   

This event focused on reviewing and celebrating the success of Velcade, a breakthrough product for patients with multiple myeloma and other hematologic cancers.   Today, Velcade is considered the gold standard of care for patients with multiple myeloma and is approved in over 90 countries worldwide.

This forum had a special significance for Veristat, since we were involved from the beginning of the clinical program in the design and analysis of the pivotal trial, and in the creation of the submission documents.  Veristat co-founders John and Barbara Balser were acknowledged for their role, as well as that of the entire Veristat team, as major contributors to the scientific collaboration underlying the submission process that lead to regulatory approval.    

The discussion was led by Julian Adams, PhD, Chief Scientific Officer & President at ClaI Biotechnology Industries; Kenneth C. Anderson, MD, Kraft Family Professor of Medicine at Harvard Medical School and Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute; Alfred Goldberg, PhD, Professor in Department of Cell Biology at Harvard Medical School; and David Schenkein, M.D., Chief Executive Officer at Agios Pharmaceuticals. They provided a fascinating glimpse into the efforts of numerous dedicated scientists and clinicians who took this product from an idea at Harvard Medical school to a biotech startup that faced  the tumult of mergers and acquisitions, and who championed the product from inception in the laboratory through clinical development and on to successful approval in record time. This was a well-attended forum that provided incredible insights into the dedication required to bring a ground-breaking therapeutic to patients in need.


Email Headshot_John Balser.png"We at Veristat are proud and honored to have played a part in this success story of Velcade, one today’s most important and life-saving oncology therapies."  

-John Balser, PhD, President, Veristat





View Event Webcast

If you missed this event,  you may view the MassBio Webcast at:

View MassBio Webcast


Learn More About Veristat’s Service Offerings

We help pharmaceutical, biotechnology and medical device firms advance through the clinical development process in order to bring their therapies to patients who need them. Explore how Veristat can help you.

Learn More

Rolling Review mechanisms and CMAs (Conditional Marketing Authorisations) have made it possible to speed up the approval of treatments against Covid-19

GENESIS BIOMED recently interviewed Xavier Luria, former Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA), and now...

Read More

Shortening Development and Approval Timelines for Novel Medicinal Products

The FDA and EMA offer expedited regulatory approval pathways to accelerate time-to-market for novel therapies intended to treat serious conditions...

Read More

Marketing Application Publishing Best Practices

Effectively managing the publishing of documents required for a marketing application submission can help accelerate the time it takes to bring your...

Read More